New drug UCB9741 tested for safety in healthy people
NCT ID NCT06315335
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a single dose of UCB9741 in 40 healthy adults, including both Caucasian and Japanese participants. Half received the drug and half a placebo, with neither participants nor researchers knowing who got what. The study focused on side effects and how the drug moves through the body, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UCB9741
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, so it cannot show whether the drug works for any disease. The main goal is safety, not treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Up0118 10001
Glendale, California, 91206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates